Cargando…

Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features

BACKGROUND: Systemic sclerosis (SSc) is a severe, progressive multiorgan disease but to date, there are no established standardised international guidelines for follow-up of patients with SSc. The goal of this project was to develop an expert consensus for annual systematic investigations in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann-Vold, Anna-Maria, Distler, Oliver, Murray, Baron, Kowal-Bielecka, Otylia, Khanna, Dinesh, Allanore, Yannick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446182/ https://www.ncbi.nlm.nih.gov/pubmed/30997150 http://dx.doi.org/10.1136/rmdopen-2018-000826

Ejemplares similares

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes
por: Gegenava, Tea, et al.
Publicado: (2023)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Association of Anti–Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Anti–Topoisomerase I–Positive Systemic Sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2020)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Sustained complete B cell depletion is associated with rituximab efficacy in connective tissue disorders-associated interstitial lung disease
por: Al Tabaa, Omar, et al.
Publicado: (2023)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

Patient and healthcare professional eHealth literacy and needs for systemic sclerosis support: a mixed methods study
por: Kocher, Agnes, et al.
Publicado: (2021)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study
por: Cutolo, Maurizio, et al.
Publicado: (2016)

Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
por: Khanna, Dinesh, et al.
Publicado: (2022)

Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review
por: Petelytska, Liubov, et al.
Publicado: (2023)

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
por: Hughes, M., et al.
Publicado: (2016)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis
por: Carvalheiro, Tiago, et al.
Publicado: (2019)

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis
por: Martin, Mickaël, et al.
Publicado: (2019)

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis
por: Ariani, Alarico, et al.
Publicado: (2019)

A stretchable hardness sensor for the assessment of skin disease in systemic sclerosis
por: Wang, Xiuyuan, et al.
Publicado: (2023)

Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers
por: Dumitru, Raluca B, et al.
Publicado: (2021)

Work Productivity and Economic Burden of Systemic Sclerosis in a Multiethnic Asian Population
por: Xiang, Ling, et al.
Publicado: (2022)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Molecular Basis for Dysregulated Activation of NKX2‐5 in the Vascular Remodeling of Systemic Sclerosis
por: Dritsoula, Athina, et al.
Publicado: (2018)

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies
por: Liem, Sophie I E, et al.
Publicado: (2023)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Risk of kidney failure in patients with systemic sclerosis: a nationwide population-based study
por: Kwon, Oh Chan, et al.
Publicado: (2023)

New risk model is able to identify patients with a low risk of progression in systemic sclerosis
por: van Leeuwen, Nina Marijn, et al.
Publicado: (2021)

Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study
por: Kida, Takashi, et al.
Publicado: (2022)

Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients
por: Beretta, Lorenzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dl6kiln14a3euu4k7ckbf8pre1